Chronic hepatitis B virus infection increases the risk of kidney disease while antiviral therapy for hepatitis B virus can decrease kidney disease risk
HBV infection contributes to the development of KD, and anti-HBV treatment can lower KD risk. As such, clinicians should consider screening patients for HBV infection or initiating treatment early, particularly in patients with risk factors for KD.
Authors
- Andrew King (ORCID: https://orcid.org/0000-0003-0517-3712)
- Catherine Frenette (ORCID: https://orcid.org/0000-0002-2245-8173)
- Leland J. Yee (ORCID: https://orcid.org/0000-0002-0369-5878)
- Yuqing Zhang (ORCID: https://orcid.org/0000-0001-7638-0888)
- Frida Abramov (ORCID: https://orcid.org/0009-0006-7509-1121)
- Kaori Ito (ORCID: https://orcid.org/0000-0001-6380-6755)
- Biao Li (ORCID: https://orcid.org/0000-0002-0493-2062)
- Vladislav A. Malkov
- John F Flaherty
Institutions
- Scripps Health (US)
- Gilead Sciences (United States) (US)
- Scripps Clinic (US)
Publication Details
- Journal
- BMC Nephrology
- Published
- 2025-04-02
- DOI
- https://doi.org/10.1186/s12882-025-03991-x
- Citations
- 1
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.35
Funders
- Gilead Sciences